During the past decade, CHU Mont -Godinne conducted 168 clinical trials. In the 10-year time frame, 168 clinical trials started and 78 clinical trials were completed, i.e. on average, 46.4% percent of trials that started reached the finish line to date. In the past 5 years, 64 clinical trials started and 46 clinical trials were completed. i.e. 71.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Mont -Godinne" #1 sponsor was "Hoffmann-La Roche" with 30 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 21 trials sponsored, "Celgene" with 19 trials sponsored, "The Lymphoma Academic Research Organisation" with 18 trials sponsored and "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 18 trials sponsored. Other sponsors include 185 different institutions and companies that sponsored additional 116 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Mont -Godinne" #1 collaborator was "Breast International Group" with 6 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Hoffmann-La Roche" with 4 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator and "Bristol-Myers Squibb" with 3 trials as a collaborator. Other collaborators include 156 different institutions and companies that were collaborators in the rest 127 trials.

According to Clinical.Site data, the most researched conditions in "CHU Mont -Godinne" are "Breast Cancer" (18 trials), "Multiple Myeloma" (15 trials), "Acute Myeloid Leukemia" (7 trials), "Myelodysplastic Syndromes" (7 trials) and "Lymphoma" (6 trials). Many other conditions were trialed in "CHU Mont -Godinne" in a lesser frequency.

Most popular intervention types in "CHU Mont -Godinne" are "Drug" (240 trials), "Biological" (27 trials), "Other" (23 trials), "Procedure" (18 trials) and "Radiation" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Rituximab" (15 trials), "Carboplatin" (14 trials), "Paclitaxel" (13 trials) and "Lenalidomide" (12 trials). Other intervention names were less common.

The vast majority of trials in "CHU Mont -Godinne" are 248 trials for "All" genders, 35 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are 94 active trials in "CHU Mont -Godinne". 1 are not yet recruiting, 44 are recruiting, 47 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 143 completed trials in CHU Mont -Godinne, 1 suspended trials, and 38 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Mont -Godinne, 18 "Phase 1" clinical trials were conducted, 101 "Phase 2" clinical trials and 133 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 13 trials that are defined as “Not Applicable".

CHU Mont -Godinne has several departments that took part in Clinical trials: "Clinique Sainte-Elisabeth; Oncologie" - 3 trials, "CHU UCL Namur, Mont-Godinne, Neurology Department, Stroke Unit" - 2 trials, "Cliniques Universitaires ULC de Mont-Godinne - Hematology" - 2 trials